XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.3

SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

SCHEDULE OF BREAKDOWN OF SIGNIFICANT OPERATING EXPENSES

SCHEDULE OF BREAKDOWN OF SIGNIFICANT OPERATING EXPENSES

		2025				2024				2025				2024
		Three months ended September 30,								Nine months ended September 30,
		2025				2024				2025				2024
Revenue		$	-			$	487			$	-			$	581
Cost of revenues			-				(60	)			-				96
Gross profit			-				547				-				485
Operating expenses:
Research and development by significant expense:
MSA/license fees			510				767				1,810				2,392
Study fees			60				48				472				200
Professional fees			233				64				591				152
Payroll and related			123				71				365				518
Other1			109				51				242				184
Research and development			1,035				1,001				3,480				3,446
General and administrative by significant expense:
Stock-based compensation			284				392				1,123				1,036
Payroll and related			313				367				1,134				1,234
Professional fees			215				1,125				1,041				3,409
Occupancy expense			6				1,267				21				5,068
Other2			140				230				426				845
General and administrative			958				3,381				3,745				11,592
Gain on lease termination			-				(1,576	)			-				(1,576	)
Total operating expenses			1,993				2,806				7,225				13,462
Loss from operations			(1,993	)			(2,259	)			(7,225	)			(12,977	)
Other income (expense), net
Forward sales contract expense			-				-				(5,847	)			-
Gain (loss) on extinguishment of debt			734				(22,440	)			734				(22,440	)
Fair value adjustments to bridge notes derivative liability			-				(1,038	)			-				(1,038	)
Change in fair value of warrant liabilities			-				831				1				897
Change in fair value of contingent consideration			-				-				-				66
Interest income (expense), net			31				(1,686	)			36				(3,269	)
Other expense, net			(6	)			-				(264	)			-
Total other income (expense), net			759				(24,333	)			(5,340	)			(25,784	)
Loss before income taxes			(1,234	)			(26,592	)			(12,565	)			(38,761	)
Provision for income taxes			(6	)			(12	)			(17	)			(19	)
Net loss		$	(1,240	)		$	(26,604	)		$	(12,582	)		$	(38,780	)

		September 30, 2025				December 31, 2024
Cash		$	3,047			$	1,729

¹ Other includes certain lab supply expenses, amounts related to the close out of a former clinical trial, allocated occupancy costs, stock-based compensation, and depreciation.

² Other includes expenses related to insurance, information technology, travel, banking, depreciation and other miscellaneous expenses.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration